Gonorrhoea is becoming increasingly resistant to antibiotics, warns WHO, citing new data from its Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP), which monitors the spread of drug-resistant gonorrhoea.
The report highlights the need to strengthen surveillance, improve diagnostic capacity and ensure equitable access to new treatments for sexually transmitted infections (STIs).
The release of the this latest data coincides with World Antimicrobial Resistance (AMR) Awareness Week, reinforcing the importance of global action against drug-resistant infections. EGASP, launched by WHO in 2015, collects laboratory and clinical data from sentinel sites worldwide to track AMR and inform treatment guidelines.
“This global effort is essential to tracking, preventing, and responding to drug-resistant gonorrhoea and to protecting public health worldwide,” said Dr Tereza Kasaeva, Director of the WHO Department for HIV, TB, Hepatitis & STIs.
Between 2022 and 2024, resistance to ceftriaxone and cefixime, the primary antibiotics used to treat gonorrhoea, rose sharply from 0.8% to 5% and from 1.7% to 11% respectively, with resistant strains detected in more countries. Resistance to azithromycin remained stable at 4%, while resistance to ciprofloxacin reached 95%. Cambodia and Viet Nam reported the highest resistance rates.
In 2024, 12 EGASP countries in five WHO regions provided data, an increase from just four countries in 2022. This is a positive development reflecting growing commitment to track and contain drug-resistant infections in countries and regions.
The countries – South Africa, Brazil, Cambodia, India, Indonesia, Malawi, the Philippines, Qatar, Sweden, Thailand, Uganda and Viet Nam – reported 3 615 cases of gonorrhoea.
More than half of all cases of symptomatic gonorrhoea in men (52%) were reported from countries in the WHO Western Pacific Region, including the Philippines (28%), Viet Nam (12%), Cambodia (9%) and Indonesia (3%).
Countries of the WHO African Region accounted for 28% of cases, followed by countries in the South-East Asia Region (13%, Thailand), the Eastern Mediterranean Region (4%, Qatar) and the Region of the Americas (2%, Brazil).
The median patient age was 27 years (range: 12–94). Among cases, 20% were men who have sex with men, and 42% reported multiple sexual partners within the past 30 days: 8% reported recent antibiotic use, and 19% had travelled recently.
Strengthening, expanding global surveillance
In 2024, WHO advanced genomic surveillance, with nearly 3 000 samples sequenced from eight countries. Landmark studies on new treatments such as zoliflodacin and gepotidacin, as well as studies on tetracycline resistance, were conducted by WHO’s Collaborating Centre on AMR in STI in Sweden, in co-ordination with WHO.
These are helping guide future gonorrhoea control and doxycycline-based prevention (DoxyPEP) strategies.
EGASP continued to expand its reach in 2024, with Brazil, Côte d’Ivoire and Qatar joining the programme, and India beginning implementation and data reporting starting in 2025 under its National Aids and Sexually Transmitted Diseases Control Programme.
Despite notable progress, EGASP faces challenges, including limited funding, incomplete reporting, and gaps in data from women and extragenital sites. WHO calls for urgent investment, particularly in national surveillance systems, to sustain and expand global gonococcal AMR surveillance.
See more from MedicalBrief archives:
FDA grants priority review for oral gonorrhoea antibiotic
Concern as ‘super-strength’ gonorrhoea gets more drug resistant
EU reports 17% rise in confirmed cases of gonorrhoea